| A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy EJ Hsu, X Cao, B Moon, J Bae, Z Sun, Z Liu, YX Fu Nature communications 12 (1), 2768, 2021 | 83 | 2021 |
| Next-generation cytokines for cancer immunotherapy D Xue, E Hsu, YX Fu, H Peng Antibody therapeutics 4 (2), 123-133, 2021 | 68 | 2021 |
| Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance X Cao, Y Liang, Z Hu, H Li, J Yang, EJ Hsu, J Zhu, J Zhou, YX Fu Nature communications 12 (1), 5866, 2021 | 60 | 2021 |
| Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells L Liu, J Chen, J Bae, H Li, Z Sun, C Moore, E Hsu, C Han, J Qiao, YX Fu Nature biomedical engineering 5 (11), 1261-1273, 2021 | 53 | 2021 |
| Direct Measurement of Cardiac Na+ Channel Conformations Reveals Molecular Pathologies of Inherited Mutations Z Varga, W Zhu, AR Schubert, JL Pardieck, A Krumholz, EJ Hsu, ... Circulation: Arrhythmia and Electrophysiology 8 (5), 1228-1239, 2015 | 43 | 2015 |
| Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity Z Liu, C Han, C Dong, A Shen, E Hsu, Z Ren, C Lu, L Liu, A Zhang, ... Science immunology 4 (38), eaav6473, 2019 | 36 | 2019 |
| IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer J Bae, L Liu, C Moore, E Hsu, A Zhang, Z Ren, Z Sun, X Wang, J Zhu, ... Nature cell biology 24 (12), 1754-1765, 2022 | 34 | 2022 |
| Regulation of Na+ channel inactivation by the DIII and DIV voltage-sensing domains EJ Hsu, W Zhu, AR Schubert, T Voelker, Z Varga, JR Silva Journal of General Physiology 149 (3), 389-403, 2017 | 31 | 2017 |
| Outcome and immune correlates of a phase II trial of high-dose interleukin-2 and stereotactic ablative radiotherapy for metastatic renal cell carcinoma R Hannan, O Mohamad, A Diaz de Leon, S Manna, LM Pop, Z Zhang, ... Clinical Cancer Research 27 (24), 6716-6725, 2021 | 18 | 2021 |
| Impact of CDKN2A/B, MTAP, and TERT genetic alterations on survival in IDH wild type glioblastomas EJ Hsu, J Thomas, EA Maher, M Youssef, RD Timmerman, Z Wardak, ... Discover Oncology 13 (1), 126, 2022 | 14 | 2022 |
| Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients EJ Hsu, J Thomas, EA Maher, M Youssef, RD Timmerman, Z Wardak, ... Frontiers in Oncology 12, 1000280, 2022 | 8 | 2022 |
| 3D printed integrated bolus/headrest for radiation therapy for malignancies involving the posterior scalp and neck EJ Hsu, D Parsons, T Chiu, AR Godley, DJ Sher, DT Vo 3D Printing in Medicine 8 (1), 22, 2022 | 6 | 2022 |
| Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy AD Sherry, P Msaouel, ZR McCaw, J Abi Jaoude, EJ Hsu, R Kouzy, ... European Journal of Cancer 194, 113357, 2023 | 5 | 2023 |
| Socioeconomic and demographic determinants of radiation treatment and outcomes in glioblastoma patients EJ Hsu, J Thomas, RD Timmerman, Z Wardak, TD Dan, TR Patel, ... Frontiers in Neurology 13, 1024138, 2022 | 2 | 2022 |
| T Stage and Pretreatment Standardized Uptake Values Predict Tumor Recurrence With 5-Fraction SABR in Early-Stage Non-Small Cell Lung Cancer EJ Hsu, JT Mendel, KA Ward, M El-Ashmawy, M Lee, H Choy, ... Advances in Radiation Oncology 7 (5), 100995, 2022 | 1 | 2022 |
| Association of differential censoring with survival and suboptimal control arms among oncology clinical trials EJ Hsu, TA Lin, DR Dabush, Z McCaw, A Koong, C Lin, J Abi Jaoude, ... JNCI: Journal of the National Cancer Institute, djae028, 2024 | | 2024 |
| Modeling gamma knife radiosurgical toxicity for multiple brain metastases EJ Hsu, Y Yan, RD Timmerman, Z Wardak, TD Dan, TR Patel, DT Vo, ... Radiotherapy and Oncology 188, 109874, 2023 | | 2023 |
